MRK
Merck & Co., Inc.
$119.05
-1.42%
$294.0B
No data for this timeframe.
Vol
Market Cap$294.0B
Cap SizeMega Cap
Analyst ConsensusBuy (69%)
Inst. Holders50 funds
Inst. Value$144.7B
Inst. Activity29 buys / 21 sells
Reddit Sentiment75° Bullish
SEC Reports4
Congressional2 trades
Recent Activity
Oct 4, 2026
fda_pdufa
PDUFA: MRK — WELIREG in previously treated patients with advanced RCC — 2026-10-04
FDA target action date 2026-10-04 for MRK (Merck & Co., Inc.). Drug: WELIREG. Indication: previously
May 31, 2026
SEC
13 firms acted on MRK: RBC Capital, Barclays, Wolfe Research, BMO Capital, Wells Fargo, Berenberg, Citigroup, Cantor Fitzgerald, Deutsche Bank, Truist Securities, BMO Capital, Wolfe Research, Bernstein
ANALYST-UPGRADE — Impact 2/10
May 29, 2026
Insider
BAKER DOUGLAS M JR was granted 1,853.1 shares
Director @ $118.72 ($220.0K)
May 29, 2026
Insider
Craig Pamela J. was granted 1,853.1 shares
Director @ $118.72 ($220.0K)
May 29, 2026
Insider
GLOCER THOMAS H was granted 1,853.1 shares
Director @ $118.72 ($220.0K)
May 22, 2026
SEC
Merck issued $4.0 billion in aggregate principal amount of new senior unsecured notes across six tranches on May 22, 202
8-K — Impact 3/10
May 1, 2026
SEC
Wolfe Research upgrades MRK to Outperform — PT $135 (+24%)
ANALYST-UPGRADE — Impact 1/10
Inst.
Nuveen, LLC — ADD
10,099,764 shares ($1.2B)
Price Targets
$129.74
+9.0% upside
Buy
Current $119.05
Low $100.00
Median $135.00
High $150.00
27 analysts
$100.00
$150.00
Analyst Ratings
9Strong Buy
16Buy
11Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 1, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Apr 13, 2026 | UBS | MAINTAIN | Buy → Buy |
| Apr 6, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Mar 30, 2026 | RBC Capital | REITERATE | Outperform → Outperform |
| Mar 20, 2026 | Citigroup | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.15 ▼ -107.4% | $-0.33 — $0.01 | -107% YoY | 5 |
| Next Q | $2.31 | $2.11 — $2.56 | -11% YoY | 5 |
| Current FY | $2.74 | $2.61 — $2.92 | -70% YoY | 7 |
| Next FY | $9.56 | $8.90 — $9.87 | 249% YoY | 9 |
Latest Reports
BULLISH
ANALYST-UPGRADE
2/10
13 firms acted on MRK: RBC Capital, Barclays, Wolfe Research, BMO Capital, Wells Fargo, Berenberg, Citigroup, Cantor Fitzgerald, Deutsche Bank, Truist Securities, BMO Capital, Wolfe Research, Bernstein
May 31, 2026
BULLISH
ANALYST-UPGRADE
1/10
Wolfe Research upgrades MRK to Outperform — PT $135 (+24%)
May 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $27.2B | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $19.4B | — |
| STATE STREET CORP | $14.5B | — |
| WELLINGTON MANAGEMENT GROUP LLP | $10.1B | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $8.1B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 29, 2026 | BAKER DOUGLAS | A | $220.0K |
| May 29, 2026 | Craig Pamela | A | $220.0K |
| May 29, 2026 | GLOCER THOMAS | A | $220.0K |
| May 29, 2026 | THULIN INGE | A | $220.0K |
| May 29, 2026 | Rothman Paul | A | $220.0K |
Reddit Sentiment
75°
Bullish
Bearish
Neutral
Bullish
Congressional Trades
2 members: 1 buys, 1 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Joshua Gottheimer | D | BUY | $1,001 - $15,000 |
| Michael McCaul | R | SELL | $15,001 - $50,000 |
50 institutional holders with $144.7B total value (1,203,433,199 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 29 institutions added/increased vs 21 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 225,830,330 | $27.2B | 18.8% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 160,987,624 | $19.4B | 13.4% | — |
| 3 | STATE STREET CORP | 119,325,673 | $14.5B | 10.0% | — |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 84,314,971 | $10.1B | 7.0% | — |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 67,304,305 | $8.1B | 5.6% | — |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 49,765,225 | $6.0B | 4.1% | — |
| 7 | MORGAN STANLEY | 47,632,487 | $5.7B | 4.0% | — |
| 8 | FMR LLC | 44,516,010 | $5.4B | 3.7% | — |
| 9 | BANK OF AMERICA CORP /DE/ | 30,774,221 | $3.7B | 2.6% | — |
| 10 | Invesco Ltd. | 21,855,101 | $2.6B | 1.8% | — |
| 11 | GOLDMAN SACHS GROUP INC | 20,133,379 | $2.4B | 1.7% | — |
| 12 | Legal & General Group Plc | 19,538,545 | $2.4B | 1.6% | — |
| 13 | AMERIPRISE FINANCIAL INC | 16,262,708 | $2.0B | 1.4% | — |
| 14 | FRANKLIN RESOURCES INC | 16,267,205 | $2.0B | 1.4% | — |
| 15 | DIMENSIONAL FUND ADVISORS LP | 15,456,039 | $1.9B | 1.3% | — |
| 16 | VANGUARD FIDUCIARY TRUST CO | 13,964,179 | $1.7B | 1.2% | — |
| 17 | Amundi | 13,764,954 | $1.7B | 1.1% | — |
| 18 | ROYAL BANK OF CANADA | 13,201,722 | $1.6B | 1.1% | — |
| 19 | DEUTSCHE BANK AG\ | 12,540,774 | $1.5B | 1.0% | — |
| 20 | HARRIS ASSOCIATES L P | 12,366,933 | $1.5B | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Nuveen, LLC | ADD | 6,958,069 | 10,099,764 | +45.2% | $1.2B | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | 2,986,471 | 5,159,124 | +72.7% | $620.6M | 2026-Q1 |
| LAZARD ASSET MANAGEMENT LLC | TRIM | 4,407,041 | 3,254,331 | -26.2% | $391.5M | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | 9,944,123 | 2,936,330 | -70.5% | $353.2M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | ADD | 1,885,140 | 2,880,199 | +52.8% | $346.5M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 3,969,469 | 2,778,301 | -30.0% | $334.2M | 2026-Q1 |
| MACKENZIE FINANCIAL CORP | ADD | 1,464,985 | 2,517,435 | +71.8% | $302.8M | 2026-Q1 |
| Alyeska Investment Group, L.P. | ADD | 1,576,712 | 2,305,574 | +46.2% | $277.3M | 2026-Q1 |
| OMERS ADMINISTRATION Corp | DOUBLED | 275,613 | 1,598,927 | +480.1% | $192.3M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 588,969 | 1,543,397 | +162.1% | $185.7M | 2026-Q1 |
| M&T BANK CORP | DOUBLED | 45,898 | 1,453,030 | +3065.8% | $174.8M | 2026-Q1 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | TRIM | 1,963,787 | 1,345,718 | -31.5% | $161.9M | 2026-Q1 |
| COMMERCE BANK | ADD | 932,790 | 1,188,031 | +27.4% | $142.9M | 2026-Q1 |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | ADD | 797,029 | 1,182,179 | +48.3% | $142.2M | 2026-Q1 |
| Zurich Insurance Group Ltd/FI | ADD | 529,303 | 967,598 | +82.8% | $116.4M | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 1,338,449 | 921,077 | -31.2% | $110.8M | 2026-Q1 |
| MACQUARIE GROUP LTD | TRIM | 1,768,032 | 870,918 | -50.7% | $104.8M | 2026-Q1 |
| Assenagon Asset Management S.A. | ADD | 541,572 | 743,214 | +37.2% | $89.4M | 2026-Q1 |
| Allspring Global Investments Holdings, LLC | TRIM | 902,306 | 672,535 | -25.5% | $81.3M | 2026-Q1 |
| Clark Capital Management Group, Inc. | DOUBLED | 17,818 | 640,272 | +3493.4% | $77.0M | 2026-Q1 |
| CREDIT AGRICOLE S A | TRIM | 1,197,416 | 637,765 | -46.7% | $76.7M | 2026-Q1 |
| 1832 Asset Management L.P. | TRIM | 1,171,636 | 616,840 | -47.4% | $74.2M | 2026-Q1 |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | ADD | 469,388 | 596,468 | +27.1% | $71.7M | 2026-Q1 |
| Holocene Advisors, LP | TRIM | 885,760 | 572,467 | -35.4% | $68.9M | 2026-Q1 |
| NATIXIS | ADD | 308,772 | 510,056 | +65.2% | $61.4M | 2026-Q1 |
23 unique insiders with 50 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | BAKER DOUGLAS M JR | Director | AWARD | 1,853.1 | $118.72 | $220.0K |
| May 29, 2026 | Craig Pamela J. | Director | AWARD | 1,853.1 | $118.72 | $220.0K |
| May 29, 2026 | GLOCER THOMAS H | Director | AWARD | 1,853.1 | $118.72 | $220.0K |
| May 29, 2026 | THULIN INGE G | Director | AWARD | 1,853.1 | $118.72 | $220.0K |
| May 29, 2026 | Rothman Paul | Director | AWARD | 1,853.1 | $118.72 | $220.0K |
| May 29, 2026 | LAVIZZO-MOUREY RISA J | Director | AWARD | 1,853.1 | $118.72 | $220.0K |
| May 29, 2026 | Mayo Stephen | Director | AWARD | 1,853.1 | $118.72 | $220.0K |
| May 29, 2026 | Coe Mary Ellen | Director | AWARD | 1,853.1 | $118.72 | $220.0K |
| May 29, 2026 | Seidman Christine E | Director | AWARD | 1,853.1 | $118.72 | $220.0K |
| May 29, 2026 | RUSSO PATRICIA F | Director | AWARD | 1,853.1 | $118.72 | $220.0K |
| May 29, 2026 | Karsanbhai Surendralal Lanca | Director | AWARD | 1,853.1 | $118.72 | $220.0K |
| May 5, 2026 | Zachary Jennifer | EVP, General Counsel | AWARD | 35,312 | — | — |
| May 5, 2026 | Zachary Jennifer | EVP, General Counsel | AWARD | 12,064 | — | — |
| May 5, 2026 | Williams David Michael | EVP,Chief Info&Digital Officer | AWARD | 13,582 | — | — |
| May 5, 2026 | Williams David Michael | EVP,Chief Info&Digital Officer | AWARD | 4,640 | — | — |
| May 5, 2026 | Litchfield Caroline | EVP & CFO | AWARD | 46,566 | — | — |
| May 5, 2026 | Litchfield Caroline | EVP & CFO | AWARD | 15,908 | — | — |
| May 5, 2026 | Li Dean Y | Executive VP & President, MRL | AWARD | 58,207 | — | — |
| May 5, 2026 | Li Dean Y | Executive VP & President, MRL | AWARD | 19,885 | — | — |
| May 5, 2026 | Larson Betty D | EVP, Chief HR Officer | AWARD | 23,283 | — | — |
| May 5, 2026 | Larson Betty D | EVP, Chief HR Officer | AWARD | 7,954 | — | — |
| May 5, 2026 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | AWARD | 34,924 | — | — |
| May 5, 2026 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | AWARD | 11,931 | — | — |
| May 5, 2026 | Davis Robert M | Chairman, CEO & President | AWARD | 139,697 | — | — |
| May 5, 2026 | Davis Robert M | Chairman, CEO & President | AWARD | 47,724 | — | — |
| May 5, 2026 | Foard Brian | EVP, Specialty, Pharma, & ID | AWARD | 31,044 | — | — |
| May 5, 2026 | Foard Brian | EVP, Specialty, Pharma, & ID | AWARD | 10,605 | — | — |
| May 5, 2026 | Maraldo David R. | EVP & Pres. MMD | AWARD | 21,731 | — | — |
| May 5, 2026 | Maraldo David R. | EVP & Pres. MMD | AWARD | 7,424 | — | — |
| May 5, 2026 | Oosthuizen Johannes Jacobus | EVP, Oncology & Int?l | AWARD | 31,044 | — | — |
| May 5, 2026 | Smart Dalton E. III | SVP Fin. - Global Controller | AWARD | 5,045 | — | — |
| May 5, 2026 | Guindo Chirfi | EVP, Access, Policy & Comms | AWARD | 19,402 | — | — |
| May 5, 2026 | Guindo Chirfi | EVP, Access, Policy & Comms | AWARD | 6,628 | — | — |
| May 5, 2026 | Smart Dalton E. III | SVP Fin. - Global Controller | AWARD | 2,298 | — | — |
| May 5, 2026 | Oosthuizen Johannes Jacobus | EVP, Oncology & Int?l | AWARD | 10,605 | — | — |
| May 2, 2026 | Smart Dalton E. III | SVP Fin. - Global Controller | EXERCISE | 383 | $112.16 | $43.0K |
| May 2, 2026 | Smart Dalton E. III | SVP Fin. - Global Controller | TAX W/H | 132 | $112.16 | $14.8K |
| May 2, 2026 | Maraldo David R. | EVP & Pres. MMD | EXERCISE | 552 | $112.16 | $61.9K |
| May 2, 2026 | Maraldo David R. | EVP & Pres. MMD | TAX W/H | 159 | $112.16 | $17.8K |
| Apr 30, 2026 | Larson Betty D | EVP, Chief HR Officer | EXERCISE | 11,350 | $110.95 | $1.3M |
| Apr 30, 2026 | Larson Betty D | EVP, Chief HR Officer | TAX W/H | 5,143 | $110.95 | $570.6K |
| Apr 30, 2026 | Smart Dalton E. III | SVP Fin. - Global Controller | EXERCISE | 464 | $110.95 | $51.5K |
| Apr 30, 2026 | Smart Dalton E. III | SVP Fin. - Global Controller | TAX W/H | 159 | $110.95 | $17.6K |
| Apr 29, 2026 | Davis Robert M | Chairman, CEO & President | TAX W/H | 6,551 | $110.03 | $720.8K |
| Apr 29, 2026 | Oosthuizen Johannes Jacobus | EVP, Oncology & Int?l | EXERCISE | 1,377 | $110.03 | $151.5K |
| Apr 29, 2026 | Oosthuizen Johannes Jacobus | EVP, Oncology & Int?l | TAX W/H | 679 | $110.03 | $74.7K |
| Apr 29, 2026 | Davis Robert M | Chairman, CEO & President | EXERCISE | 13,300 | $110.03 | $1.5M |
| Apr 29, 2026 | Litchfield Caroline | EVP & CFO | EXERCISE | 3,935 | $110.03 | $433.0K |
| Apr 29, 2026 | Litchfield Caroline | EVP & CFO | TAX W/H | 1,938 | $110.03 | $213.2K |
| Apr 29, 2026 | Larson Betty D | EVP, Chief HR Officer | EXERCISE | 2,085 | $110.03 | $229.4K |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 2.0/10.
BULLISH
ANALYST-UPGRADE
1/10
Wolfe Research upgrades MRK to Outperform — PT $135 (+24%)
May 1, 2026
BULLISH
ANALYST-UPGRADE
2/10
13 firms acted on MRK: RBC Capital, Barclays, Wolfe Research, BMO Capital, Wells Fargo, Berenberg, Citigroup, Cantor Fitzgerald, Deutsche Bank, Truist Securities, BMO Capital, Wolfe Research, Bernstein
May 31, 2026
NEUTRAL
8-K
3/10
Merck issued $4.0 billion in aggregate principal amount of new senior unsecured notes across six tra
May 22, 2026
NEUTRAL
DEFA14A
2/10
Merck's 2026 proxy statement is a routine filing for the annual shareholder meeting, proposing the e
Apr 8, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (69% buy). Based on 36 analysts: 9 strong buy, 16 buy, 11 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$129.74 mean target
+9.0% upside
Buy (1.83)
$100.00 Low
$150.00 High
| Metric | Value |
|---|---|
| Current Price | $119.05 |
| Target Low | $100.00 |
| Target Mean | $129.74 |
| Target Median | $135.00 |
| Target High | $150.00 |
| # Analysts | 27 |
| Recommendation | Buy (1.83) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.15 | $-0.33 | $0.01 | -107.2% | -107.4% | 0↑ 3↓ | $16.4B | 3.7% | 5 |
| Next Q 2026-09-30 |
$2.31 | $2.11 | $2.56 | -10.6% | -0.4% | 1↑ 2↓ | $17.5B | 1.6% | 5 |
| Current FY 2026-12-31 |
$2.74 | $2.61 | $2.92 | -69.5% | +0.0% | 0↑ 4↓ | $66.8B | 2.8% | 7 |
| Next FY 2027-12-31 |
$9.56 | $8.90 | $9.87 | 249.5% | +0.4% | 2↑ 4↓ | $70.2B | 4.9% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.153 | |
| 7d ago | $-0.153 | |
| 30d ago | $2.080 | -2.233 |
| 60d ago | $1.930 | -2.083 |
| 90d ago | $1.942 | -2.095 |
12 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 1, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 13, 2026 | UBS | MAINTAIN | Buy | Buy |
| Apr 6, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 30, 2026 | RBC Capital | REITERATE | Outperform | Outperform |
| Mar 20, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Mar 12, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 25, 2026 | RBC Capital | INITIATE | — | Outperform |
| Feb 20, 2026 | Barclays | INITIATE | — | Overweight |
| Feb 9, 2026 | Freedom Broker | MAINTAIN | Hold | Hold |
| Feb 6, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 4, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Feb 4, 2026 | Cantor Fitzgerald | MAINTAIN | Neutral | Neutral |
| Feb 4, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 27, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Jan 20, 2026 | TD Cowen | MAINTAIN | Hold | Hold |
| Jan 8, 2026 | Wolfe Research | UPGRADE | Peer Perform | Outperform |
| Jan 7, 2026 | UBS | MAINTAIN | Buy | Buy |
| Jan 7, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Dec 18, 2025 | BMO Capital | UPGRADE | Market Perform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 16 | 11 | 0 | 0 | 69% | |
| May 1, 2026 | 8 | 17 | 10 | 0 | 0 | 71% | |
| Apr 1, 2026 | 8 | 16 | 11 | 0 | 0 | 69% | |
| Mar 1, 2026 | 8 | 16 | 12 | 0 | 0 | 67% | |
| Feb 1, 2026 | 8 | 13 | 13 | 0 | 0 | 62% | |
| Jan 1, 2026 | 7 | 15 | 12 | 0 | 0 | 65% | |
| Dec 1, 2025 | 7 | 14 | 13 | 0 | 0 | 62% | |
| Nov 1, 2025 | 7 | 12 | 14 | 0 | 0 | 58% |
Strong BuyBuyHoldSellStrong Sell
2 members of Congress traded this stock: 1 buys, 1 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | Joshua Gottheimer | D | HOUSE | BUY | $1,001 - $15,000 | Merck & Co Inc | Mar 17, 2026 (42d) |
| Jan 13, 2026 | Michael McCaul | R | HOUSE | SELL | $15,001 - $50,000 | Merck & Co Inc | Feb 12, 2026 (31d) |
75°
Bullish
Bearish
Neutral
Bullish
4 mentions
4 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 31, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 31, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Top Dividend Stocks for 2025: 6 Picks Paying 3%+
▲ 1
💬 0
⚡ 0.5
Market Screener: BAC, JPM, and MRK looking cheap? 📈
▲ 1
💬 1
⚡ 0.5
Oct 4, 2026
fda_pdufa
PDUFA: MRK — WELIREG in previously treated patients with advanced RCC — 2026-10-04
FDA target action date 2026-10-04 for MRK (Merck & Co., Inc.). Drug: WELIREG. Indication: previously treated patients with advanced RCC. FDA set PDUFA
Sep 21, 2026
fda_pdufa
PDUFA: MRK — KEYTRUDA in first-line treatment of certain patients with PD-L1+ inoperable (unresectable) locally advanced or metastatic TNBC — 2026-09-21
FDA target action date 2026-09-21 for MRK (Merck & Co., Inc.). Drug: KEYTRUDA. Indication: first-line treatment of certain patients with PD-L1+ inoper
Aug 17, 2026
fda_pdufa
PDUFA: MRK — KEYTRUDA in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC) — 2026-08-17
FDA target action date 2026-08-17 for MRK (Merck & Co., Inc.). Drug: KEYTRUDA. Indication: cisplatin-eligible patients with muscle-invasive bladder ca
Aug 4, 2026
earnings_calendar
MRK Q2 2026 Earnings After Market Close — 2026-08-04
EPS est: $1.97 | Rev est: $16.5B
Jun 19, 2026
fda_pdufa
PDUFA: MRK — WELIREG in adjuvant treatment of certain patients with RCC — 2026-06-19
FDA target action date 2026-06-19 for MRK (Merck & Co., Inc.). Drug: WELIREG. Indication: adjuvant treatment of certain patients with RCC. FDA set PDU
Jun 12, 2026
Clinical Trial
Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)
Phase Phase 3 — COMPLETED
Jun 11, 2026
Clinical Trial
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Phase Phase 2 — TERMINATED
Jun 11, 2026
Clinical Trial
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)
Phase Phase 3 — COMPLETED
Jun 11, 2026
short_volume
Short Volume: MRK — 63.0% short (3.1M / 5.0M)
Short: 3,147,068 | Exempt: 5,064 | TRF Vol: 4,994,336 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
Clinical Trial
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
Phase Phase 3 — TERMINATED
Jun 9, 2026
Clinical Trial
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
Phase Phase 2 — COMPLETED
Jun 1, 2026
clinical_trial_readout
T-90d Trial Readout: ONC-392 (Phase 2)
Trial: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Sponsor: OncoC4, Inc.
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Conditions:
Jun 1, 2026
clinical_trial_readout
T-90d Trial Readout: Avelumab (Phase 3)
Trial: Avelumab Program Rollover Study
Sponsor: EMD Serono Research & Development Institute, Inc.
Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITING
Condi
Jun 1, 2026
clinical_trial_readout
T-90d Trial Readout: pembrolizumab/vibostolimab (Phase 3)
Trial: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus C
May 31, 2026
clinical_trial_readout
Results Pending: favezelimab/pembrolizumab (Phase 2) — Completed 80d ago
Trial: Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
Sponsor: Merck Sharp
May 28, 2026
clinical_trial_readout
Results Pending: Pembrolizumab (Phase 2) — Completed 10d ago
Trial: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First
May 28, 2026
clinical_trial_readout
Results Pending: Zilovertamab vedotin (Phase 2) — Completed 37d ago
Trial: A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
Sponsor: Merc
May 26, 2026
short_volume
Short Volume: MRK — 58.9% short (2.2M / 3.7M)
Short: 2,185,749 | Exempt: 6,652 | TRF Vol: 3,710,079 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
May 25, 2026
clinical_trial_readout
T-90d Trial Readout: Avelumab (Phase 3)
Trial: Avelumab Program Rollover Study
Sponsor: EMD Serono Research & Development Institute, Inc.
Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITING
Condi
May 25, 2026
clinical_trial_readout
T-90d Trial Readout: pembrolizumab/vibostolimab (Phase 3)
Trial: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus C
Apr 20, 2026
FDA
IDVYNSOTM
Original Approval — Type 1 - New Molecular Entity and Type 4 - New Combination — TABLET
Dec 8, 2025
FDA
WINREVAIR
Supplemental Approval — Labeling — SOTATERCEPT-CSRK — INJECTABLE
Dec 8, 2025
FDA
WINREVAIR
Supplemental Approval — Labeling — SOTATERCEPT-CSRK — INJECTABLE
Dec 8, 2025
FDA
WINREVAIR
Supplemental Approval — Labeling — SOTATERCEPT-CSRK — INJECTABLE
Sep 19, 2025
FDA
KEYTRUDA QLEX
Original Approval — Type 1 - New Molecular Entity — PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH — INJECTABLE — SUBCUTANEOUS